Carbamylated hemoglobin: A potential marker for the adequacy of hemodialysis therapy in end-stage renal failure

47Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Urea can dissociate in vivo to form isocyanic acid which can react with hemoglobin to form carbamylated hemoglobin. Previous work has shown that formation of carbamylated hemoglobin depends upon both the severity and the duration of renal failure. To determine whether carbamylated hemoglobin can be used as an assessment of the adequacy of hemodialysis treatment, we prospectively studied 55 stable patients who regularly attended our hospital dialysis program. Carbamylated hemoglobin was greater in those patients with a Kt/V of ≤ 1.1 compared to those with Kt/V of > 1.1 (120 ± 8 μgVH/gHb versus 99 ± 7, P < 0.01), and there were positive correlations between carbamylated hemoglobin and the time-averaged urea concentration (r = 0.4, P = 0.004), and a negative correlation with the urea reduction ratio (r = -0.37, P = 0.01). Carbamylated hemoglobin may therefore be a useful marker of the degree of uremia, just as glycosylated hemoglobin is used in the assessment of patients with diabetes mellitus.

Cite

CITATION STYLE

APA

Davenport, A., Jones, S., Goel, S., Astley, J. P., & Feest, T. G. (1996). Carbamylated hemoglobin: A potential marker for the adequacy of hemodialysis therapy in end-stage renal failure. Kidney International, 50(4), 1344–1351. https://doi.org/10.1038/ki.1996.447

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free